Table 10 Selected studies for CLL therapy from 2020 ASH annual meeting
Abstract # | First author (reference) | Study agents | Phase | NCT | Study name |
|---|---|---|---|---|---|
127 | Al-Sawaf [111] | Venetoclax, obinutuzumab | III | NCT02242942 | CLL14 |
1310 | Al-Sawaf [112] | Venetoclax, obinutuzumab | III | NCT02242942 | CLL14 |
123 | Wierda [113] | Ibrutinib, venetoclax | II | NCT02910583 | CAPTIVATE |
3138 | Jain [115] | Ibrutinib, venetoclax | II | NCT02756897 | |
2216 | Davids [114] | Acalabrutinib, venetoclax, obinutuzumab | II | NCT03580928 | |
1307 | Soumerai [116] | Zanubrutinib, venetoclax, obinutuzumab | II | NCT03824483 | BoVen |
125 | Kater [117] | Venetoclax, rituximab | III | NCT02005471 | MURANO |
124 | Hillmen [120] | Ibrutinib, venetoclax | II | ISCRTN13751862 | CLARITY |
543 | Gribben [119] | Umbralisib, ublituximab | III | NCT02612311 | UNITY-CLL |
542 | Mato [121] | Loxo-305 | I/II | NCT03740529 | BRUIN |
545 | Benjamini [122] | CD19-CART | I | NCT02772198 | |
126 | Mato [123] | DTRM-555 | I | NCT02900716 | |
544 | Wierda [124] | Liso-cel, ibrutinib | I | NCT03331198 | TRANSCEND-004 |
546 | Siddiqi [125] | Liso-cel | I | NCT03331198 | TRANSCEND-004 |